ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 97 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $119,282 | -84.7% | 113,601 | 0.0% | 0.00% | – |
| Q3 2023 | $778,166 | +9.3% | 113,601 | +29.1% | 0.00% | – |
| Q2 2023 | $712,049 | 0.0% | 88,016 | 0.0% | 0.00% | – |
| Q1 2023 | $712,049 | -48.6% | 88,016 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $1,386,253 | -99.9% | 88,016 | +1.5% | 0.00% | 0.0% |
| Q3 2022 | $1,364,753,000 | +13.3% | 86,706 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $1,204,288,000 | +41.6% | 86,267 | +74.8% | 0.00% | – |
| Q1 2022 | $850,726,000 | +18.6% | 49,346 | 0.0% | 0.00% | – |
| Q4 2021 | $717,491,000 | +9.3% | 49,346 | +35.3% | 0.00% | – |
| Q3 2021 | $656,388,000 | +19.5% | 36,466 | +16.6% | 0.00% | – |
| Q2 2021 | $549,276,000 | +706.6% | 31,280 | +175.2% | 0.00% | – |
| Q1 2019 | $68,094,000 | -71.1% | 11,368 | +18.8% | 0.00% | – |
| Q4 2017 | $235,947,000 | -96.1% | 9,568 | -95.9% | 0.00% | -100.0% |
| Q3 2017 | $6,029,113,000 | +102.0% | 233,596 | +112.3% | 0.01% | +66.7% |
| Q2 2017 | $2,984,204,000 | – | 110,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,399,034 | $49,422,000 | 10.17% |
| VR Adviser, LLC | 4,563,962 | $66,360,000 | 9.07% |
| COMMODORE CAPITAL LP | 2,672,346 | $38,856,000 | 9.00% |
| TCG Crossover Management, LLC | 1,082,213 | $15,735,000 | 7.37% |
| Foresite Capital Management V, LLC | 1,258,243 | $18,295,000 | 4.50% |
| Parkman Healthcare Partners LLC | 1,025,522 | $14,911,000 | 3.29% |
| Aisling Capital Management LP | 634,455 | $9,225,000 | 3.25% |
| GREAT POINT PARTNERS LLC | 800,000 | $11,632,000 | 2.58% |
| Samsara BioCapital, LLC | 794,171 | $11,547,000 | 2.24% |
| Affinity Asset Advisors, LLC | 400,000 | $5,816,000 | 2.11% |